November 28, 2021

Medical Trend

Medical News and Medical Resources

Chinese mRNA COVID-19 vaccine can be stored at 2-8 °C for 6 months

Chinese mRNA COVID-19 vaccine can be stored at 2-8 °C for 6 months

Chinese mRNA COVID-19 vaccine can be stored at 2-8 °C for 6 months

 

Chinese mRNA COVID-19 vaccine can be stored at 2-8 °C for 6 months.  This breakthrough in China will likely bring tremendous help to the global fight against the epidemic.

 

On May 13th, Mexico announced that it will test China’s mRNA COVID-19 vaccine! This Chinese vaccine, which represents the world’s latest vaccine drug technology level, will undergo in-depth testing in Mexico, where the epidemic is relatively severe, and it is expected to eventually break the monopoly of Western powers on mRNA technology.

 

At present, China Watson Biotech is cooperating with Suzhou Arburg Biotech Co., Ltd. and other institutions to develop ARCoV or ARCoVax vaccine, which is China’s first mRNA vaccine to enter Phase III clinical trials.

Mexican Foreign Minister Marcelo Ebrard (Marcelo Ebrard) said that Mexico plans to start late-stage clinical trials of the new coronavirus vaccine candidate developed in China this month. The vaccine uses messenger RNA technology similar to Moderna and Pfizer vaccines.

 

The foreign minister pointed out that China’s Watson Biotechnology uses mRNA technology to develop this vaccine option for testing in Mexico, which is good news. The upcoming Phase III trial will begin on May 30, with 6000 volunteers participating.

In April this year, the AMS researchers in charge of the vaccine project stated at a vaccine research event that the vaccine can be stored at a temperature of 2-8 degrees Celsius for 6 months, which is much more relaxed than the temperature requirements of Western competitors’ vaccines. . Pfizer vaccines require long-term storage at -80 degrees and can only be stored for a few days at -8 degrees.

Mexico has accepted other vaccines from institutions such as China Kexing Biotechnology Company (SVA.O) and plans to order vaccines produced by Sinopharm Group.

 

China currently uses five independently developed vaccines in its vaccination work, but none of them uses messenger RNA technology. This latest vaccine drug technology contains instructions for human cells to produce proteins that mimic some of the new coronavirus. It is highly targeted and easy to modify the design, which can better deal with mutant viruses.

Under the background of the monopoly of mRNA technology by the United States and Germany, it is difficult for countries in the world to obtain similar advanced vaccines. This breakthrough in China may bring a huge help to the global fight against the epidemic.

According to data from the online database ClinicalTrials.gov, Walvax plans to recruit approximately 28,000 participants over 18 years of age worldwide, of which 25% or over 60 years of age will be randomly assigned. Take two doses of experimental vaccine or placebo at 28 days intervals.

If the expected treatment efficiency and good safety data are achieved, the participants will receive two more doses-participants in the study group will receive a placebo, participants in the control group will receive an experimental vaccine, and their health status will be evaluated 12 months of monitoring. This means that people who receive placebo injections can still be protected from Covid-19 without revealing their group to participants. The main study is expected to be completed by the end of October.

 

(source:internet, reference only)


Disclaimer of medicaltrend.org